Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Chiesi and Protalix Get Positive CHMP Opinion for Elfabrio
Chiesi Global Rare Diseases and Protalix BioTherapeutics have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of a new every-four-week dosing regimen of Elfabrio for adult patients with Fabry disease who are stable on enzyme replacement therapy. The opinion follows a re-examination of the application and will now be reviewed by the European Commission, with a decision expected by March 2026. If approved, this regimen would reduce the frequency of infusion visits from every two weeks to every four weeks, easing the burden for patients, families, and the healthcare system.
Johnson & Johnson Gets CHMP Positive Opinion for AKEEGA in mHSPC
Johnson & Johnson has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended expanding the indication for AKEEGA, a dual action tablet containing niraparib and abiraterone acetate, for use with androgen deprivation therapy and prednisone or prednisolone in adult patients with metastatic hormone-sensitive prostate cancer who carry BRCA1 or BRCA2 mutations. This recommendation follows positive results from the Phase 3 AMPLITUDE study.
RazorMetrics Delivers $11Million in Ohio Prescription Savings
RazorMetrics, a leading innovator in pharmacy cost management, announced that it has generated over $11 million in prescription drug savings for health plans and residents across Ohio. These savings impacted nearly 60,000 covered members and highlight RazorMetrics’ ongoing ability to reduce drug spending while ensuring access to necessary medications. Rising prescription costs continue to challenge employers, health plans, and public programs nationwide. RazorMetrics addresses avoidable pharmacy waste by identifying duplicative therapies, excess supply, and opportunities to switch to clinically appropriate lower-cost alternatives, all within existing prescriber workflows.
Kos Biotechnology Partners Leads Epikast Financing Round
Kos Biotechnology Partners, a global investment firm focused on life sciences, has announced the completion of a financing round in Epikast, a provider of technology-driven commercial and clinical support services for the biopharmaceutical sector. This investment represents the first deployment from Kos’ inaugural fund, which targets opportunities across multiple stages, from early formation to scaling established healthcare platforms.
Merz Therapeutics Appoints Dan Staner as President, Region Europe
Merz Therapeutics has announced that Dan Staner will take on the role of President, Region Europe, effective February 1, 2026. In this position, Staner will be responsible for leading the company’s European operations and supporting continued growth across the region as Merz Therapeutics advances its strategic priorities.
To share your insights, please write to us at sudipto@intentamplify.com
